Skip to content

Macimorelin

Growth Hormone Secretagogue Receptor Agonist — VARIOUS

Also known as: ARD 07, D-87575, EP1572, macimorelin acetate

OfmEMA approvedFDA approvedOrphan designationATC V04CD06

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Macimorelin is an ofm drug in the Growth Hormone Secretagogue Receptor Agonist class catalogued in DrugCentral. It was first approved by the FDA in 2017. Its mechanism of action is classified as Growth Hormone Secretagogue Receptor Agonists. DrugCentral lists 1 molecular target, including GHSR.

  • Approval status: ofm (first approved 2017 by the FDA).
  • Drug class: Growth Hormone Secretagogue Receptor Agonist.
  • Mechanism of action: Growth Hormone Secretagogue Receptor Agonists.
  • Molecular targets: GHSR (1 listed in DrugCentral).
  • ATC code: V04CD06 (Tests for pituitary function).
  • Molecular formula: C26H30N6O3; molecular weight 474.56 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Diagnosis (1)

  • Adult growth hormone deficiency

Mechanism & targets

Mechanism of action (MoA)Growth Hormone Secretagogue Receptor Agonists
Established pharmacologic classGrowth Hormone Secretagogue Receptor Agonist

Molecular targets (1)

TargetGeneActionActivity
Growth hormone secretagogue receptor type 1GHSRagonistIC50 7.81

Regulatory approvals (2)

DateAgencyMarketed asApplicantOrphan
2019-01-11EMA—AETERNA ZENTARIS GMBH
2017-12-20FDA—AETERNA ZENTARIS GMBHYes

ATC classification

ATC codeTherapeutic hierarchy
V04CD06VARIOUS › DIAGNOSTIC AGENTS › OTHER DIAGNOSTIC AGENTS › Tests for pituitary function

Chemical structure

Molecular formulaC26H30N6O3
Molecular weight474.56 g/mol
CAS number—
InChIKeyVPBQKRKRYYPMOF-DHIUTWEWSA-N
PubChem CID9804938
CC(C)(N)C(=O)N[C@H](CC1=CC2=C(N1)C=CC=C2)C(=O)N[C@H](CC1=CNC2=C1C=CC=C2)NC=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

How does Macimorelin work?

Macimorelin is classified as Growth Hormone Secretagogue Receptor Agonists; its molecular targets in DrugCentral include GHSR (agonist).

When was Macimorelin first approved?

Macimorelin was first approved by the FDA in 2017.

What drug class does Macimorelin belong to?

Macimorelin is in the Growth Hormone Secretagogue Receptor Agonist class.

What is the chemical formula of Macimorelin?

Macimorelin has the molecular formula C26H30N6O3 and a molecular weight of 474.56 g/mol.

Browse: all drugs starting with M · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFM
First approval2017-12-20
AgencyFDA
Targets1
Indications0
FormulaC26H30N6O3
DrugCentral ID5271
Interactive profile